Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment
David C Seldin1, John L Berk, Flora Sam
1Amyloidosis Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston Medical Center, K5, 72 East Concord Street, Boston, MA 02118, USA. dseldin@bu.edu
Insights
Amyloidotic cardiomyopathy (ACMP) is diagnosed by cardiologists using noninvasive tests and biopsy. Early diagnosis and treatment are crucial for preserving heart function in patients with this rare condition.
Area of Science:
- Cardiology
- Genetics
- Pathology
Background:
- Amyloidotic cardiomyopathy (ACMP) presents with symptoms like dyspnea, heart failure, and arrhythmias.
- It is associated with rare genetic disorders, blood diseases, chronic inflammation, and aging.
- Cardiologists play a key role in identifying ACMP during patient evaluations.
Purpose of the Study:
- To outline the diagnostic process for ACMP.
- To emphasize the importance of timely diagnosis and treatment.
- To highlight the role of noninvasive detection and confirmatory testing.
Main Methods:
- Noninvasive detection of diastolic dysfunction and left ventricular hypertrophy.
- Cardiac biopsy to confirm amyloid deposits.
- Genetic, biochemical, and immunologic testing to classify amyloid type.
Main Results:
- Diagnostic pathway involves initial noninvasive findings followed by biopsy confirmation.
- Accurate amyloid typing is achieved through comprehensive testing.
- Effective treatment options are increasingly available.
Conclusions:
- Timely diagnosis of ACMP is essential for effective management.
- Early intervention with appropriate therapies preserves cardiac function.
- Multidisciplinary testing is vital for accurate ACMP diagnosis and treatment planning.
Abstract:
Amyloidotic cardiomyopathy (ACMP) occurs in the setting of rare genetic diseases, blood dyscrasias, chronic infection and inflammation, and advanced age. Cardiologists are on the front lines of diagnosis of ACMP when evaluating patients with unexplained dyspnea, congestive heart failure, or arrhythmias. Noninvasive detection of diastolic cardiac dysfunction and unexplained left ventricular hypertrophy should be followed by biopsy to demonstrate the presence of amyloid deposits and appropriate genetic, biochemical, and immunologic testing to accurately define the type of amyloid. Growing numbers of treatment options exist for these diseases, and timely diagnosis and institution of therapy is essential for preservation of cardiac function.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Myocarditis III: Medical Management

